The biopharmaceutical industry is a major source of innovation and a driver of development of both the global pharmaceutical market and the different national markets, including the Russian one. The development of the Russian market of biotech drugs was facilitated by the expansion of state drug supply programs and the formation of the Russian pharmaceutical industry. The aim of the study was to assess the nomenclature, volumes and values, dynamics and structure of the Russian BD market in 2013–2023. BDs were identified as medicinal products obtained using recombinant DNA technology. Materials and methods. The study was based on the state registration, patent and scientific information, as well as sales data of DSM Group. Market segmentation was carried out considering the allocated groups of BDs, as well as ATC classification system. Results and discussion. In 2023 in Russia the sales value of BD related to 168 INNs amounted to RUB 288.4 billion in wholesale prices. In the sales structure, the main BD groups were mAbs and hormones. The leading therapeutic classes were antineoplastic agents and immunosuppressants, while orphan drugs accounted for 27.3% of the sales. Since 2013, the compound annual growth rates of BD sales in Russia have exceeded the global figures. BD's share in the Russian pharmaceutical market was significantly smaller than in the global market. Market share of biosimilars mostly represented by domestic products was high. The share of Russian-made drugs mainly provided by a limited list of companies increased to 30.8% by 2023 due to the development of biosimilars and original drugs. Conclusion. The BD segment has been remained as the most actively developing part of the Russian pharmaceutical market, where are concentrated the activities of the leading Russian companies aimed at the development of biosimilars and original drugs.

biotech drugs, recombinant DNA technology, biosimilars, original drugs, monoclonal antibodies, the Russian pharmaceutical market, the Russian pharmaceutical industry.